{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:28:23Z","timestamp":1793978903148,"version":"4.8.0"},"reference-count":133,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejmech.2026.119281","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:20:29Z","timestamp":1788276029000},"page":"119281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["FDA-approved imidazole- and benzimidazole-based drugs: An update"],"prefix":"10.1016","volume":"319","author":[{"given":"Jingjing","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianxue","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuyang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danye","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"72","key":"10.1016\/j.ejmech.2026.119281_bib1","doi-asserted-by":"crossref","first-page":"44247","DOI":"10.1039\/D0RA09198G","article-title":"Prescribed drugs containing nitrogen heterocycles: an overview","volume":"10","author":"Heravi","year":"2020","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2026.119281_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115847","article-title":"Synthetic approaches and application of clinically approved small-molecule Anti-HIV drugs: an update","volume":"261","author":"Sun","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119281_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116446","article-title":"Fluorine in the pharmaceutical industry: synthetic approaches and application of clinically approved fluorine-enriched anti-infectious medications","volume":"271","author":"Niu","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2026.119281_bib4","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.3390\/molecules30102245","article-title":"Imidazole hybrids: a privileged class of heterocycles in medicinal chemistry with new insights into anticancer activity","volume":"30","author":"Murtazaeva","year":"2025","journal-title":"Molecules"},{"issue":"17","key":"10.1016\/j.ejmech.2026.119281_bib5","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.2174\/0115680266314704240522112439","article-title":"Benzimidazole as a privileged scaffold in drug design and discovery","volume":"24","author":"Kumar","year":"2024","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119281_bib6","series-title":"Drugs and Lactation Database (Lactmed\u00ae)","author":"Ketoconazole","year":"2006"},{"issue":"7","key":"10.1016\/j.ejmech.2026.119281_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.202403020","article-title":"Exploring USFDA-approved imidazole-based small molecules in drug discovery: a mini perspective","volume":"22","author":"Gupta","year":"2025","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.ejmech.2026.119281_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.rechem.2023.100925","article-title":"Benzimidazole and its derivatives: recent advances (2020\u20132022)","volume":"5","author":"Ebenezer","year":"2023","journal-title":"Results Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119281_bib9","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1039\/D4RA05014B","article-title":"Anticancer benzimidazole derivatives as inhibitors of epigenetic targets: a review article","volume":"15","author":"Wagih","year":"2025","journal-title":"RSC Adv."},{"issue":"14","key":"10.1016\/j.ejmech.2026.119281_bib10","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.3390\/molecules28145490","article-title":"A review of approaches to the metallic and non-metallic synthesis of benzimidazole (BnZ) and their derivatives for biological efficacy","volume":"28","author":"Patel","year":"2023","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119281_bib11","article-title":"Possible adverse events of imidazole antifungal drugs during treatment of vulvovaginal candidiasis: analysis of the FDA adverse event reporting system","volume":"14","author":"Zhou","year":"2024","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119281_bib12","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/myc.12168","article-title":"Luliconazole: a review of a new antifungal agent for the topical treatment of onychomycosis","volume":"57","author":"Scher","year":"2014","journal-title":"Mycoses"},{"key":"10.1016\/j.ejmech.2026.119281_bib13","series-title":"Drugs and Lactation Database (Lactmed\u00ae)","author":"Luliconazole","year":"2006"},{"key":"10.1016\/j.ejmech.2026.119281_bib14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2147\/CE.S49629","article-title":"Luliconazole for the treatment of fungal infections: an evidence-based review","volume":"9","author":"Khanna","year":"2014","journal-title":"Core Evid."},{"issue":"10","key":"10.1016\/j.ejmech.2026.119281_bib15","first-page":"20","article-title":"A randomized, double-blind, vehicle-controlled trial of luliconazole cream 1% in the treatment of interdigital Tinea Pedis","volume":"7","author":"Draelos","year":"2014","journal-title":"The Journal of clinical and aesthetic dermatology"},{"key":"10.1016\/j.ejmech.2026.119281_bib16","unstructured":"Kodama H, Niwano Y, Kanai K, Yoshida M, Inventors; Nihon Nohyaku Co., Ltd. Kodama Hiroki Niwano Yoshimi Kanai Kazuo Yoshida Masanori, Assignee. Antifungal Agents. US Patent WO97028211997."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119281_bib17","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s40265-018-0864-z","article-title":"Ledipasvir\/sofosbuvir: a review in chronic hepatitis C","volume":"78","author":"Scott","year":"2018","journal-title":"Drugs"},{"issue":"20","key":"10.1016\/j.ejmech.2026.119281_bib18","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119281_bib19","unstructured":"Guo H, Kato D, Kirschberg TA, et al., Inventors; Gilead Sciences, Inc. Kim, Choung, U., Assignee. Preparation of Biaryls, Arylheteroaryls, Heteroaryls, Biarylacetylenes and Related Compounds end-capped with Amino Acid or Peptide Derivatives as Antiviral Agents. US patent WO20101326012010."},{"key":"10.1016\/j.ejmech.2026.119281_bib20","unstructured":"Scott RW, Vitale JP, Matthews KS, Teresk MG, Formella A, Evans JW, Inventors; Gilead Sciences, Inc., Assignee. Synthesis Imidazolyl Amino Acid Derivatives as Potential Antiviral Agents. US patent WO20131847022013."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119281_bib21","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s40265-015-0436-4","article-title":"Eluxadoline: first global approval","volume":"75","author":"Garnock-Jones","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.119281_bib22","doi-asserted-by":"crossref","unstructured":"Lembo Anthony J, Lacy Brian E, Zuckerman Marc J, et al. Eluxadoline for irritable bowel syndrome with diarrhea. N. Engl. J. Med.374(3):242-253.","DOI":"10.1056\/NEJMoa1505180"},{"key":"10.1016\/j.ejmech.2026.119281_bib23","series-title":"Drugs and Lactation Database (Lactmed\u00ae)","author":"Eluxadoline","year":"2006"},{"issue":"3","key":"10.1016\/j.ejmech.2026.119281_bib24","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1124\/jpet.116.236547","article-title":"Abuse potential and pharmacodynamic characteristics of oral and intranasal eluxadoline, a mixed \u03bc- and \u03ba-Opioid receptor agonist and \u03b4-Opioid receptor antagonist","volume":"359","author":"Levy-Cooperman","year":"2016","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2026.119281_bib25","unstructured":"Breslin HJ, Cai C, He W, Kavash RW, Inventors; Janssen Pharmaceutica N.V., Assignee. Preparation of Imidazole Derivatives as Opioid Receptor Modulators. US patent US200502031432005."},{"issue":"8","key":"10.1016\/j.ejmech.2026.119281_bib26","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s40262-017-0624-3","article-title":"Daclatasvir: a review of preclinical and clinical pharmacokinetics","volume":"57","author":"Gandhi","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2026.119281_bib27","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.2147\/DDDT.S40310","article-title":"Daclatasvir: potential role in hepatitis C","volume":"7","author":"Lee","year":"2013","journal-title":"Drug Des. Dev. Ther."},{"issue":"10","key":"10.1016\/j.ejmech.2026.119281_bib28","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1073\/pnas.1203110110","article-title":"Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life","volume":"110","author":"Guedj","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejmech.2026.119281_bib29","unstructured":"Thibeault C, Edwards PJ, Kuhn C, Moreau B, Poirier M, Surprenant S, Inventors; Boehringer Ingelheim International Gmbh, Assignee. Preparation of Biphenyls end-capped with Peptide Derivatives as Inhibitors of HCV NS5A for the Treatment of Hepatitis C Viral Infection. US patent WO20120484212012."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119281_bib30","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s40265-016-0558-3","article-title":"Elbasvir\/grazoprevir: first global approval","volume":"76","author":"Keating","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.119281_bib31","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/3852126","article-title":"Elbasvir\/grazoprevir: a review of the latest agent in the fight against hepatitis C","volume":"2016","author":"Bell","year":"2016","journal-title":"International journal of hepatology"},{"issue":"2","key":"10.1016\/j.ejmech.2026.119281_bib32","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s12072-016-9761-2","article-title":"Elbasvir\/Grazoprevir for treatment of chronic hepatitis C virus infection","volume":"11","author":"Papudesu","year":"2017","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.ejmech.2026.119281_bib33","unstructured":"Mangion I, Chen C-Y, Jeon I, et al., Inventors; Merck Sharp & Dohme Corp., Assignee. Process for Preparing HCV NS5A Inhibitor Tetracyclic Heterocycle Compounds end-capped with Peptides. US patent WO20150658212015."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119281_bib34","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s40265-018-0895-5","article-title":"Sofosbuvir\/Velpatasvir\/voxilaprevir: a review in chronic hepatitis C","volume":"78","author":"Heo","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.119281_bib35","unstructured":"Allan KM, Fujimori S, Heumann LV, et al., Inventors; Gilead Pharmasset LLC, Assignee. Processes for Preparing Peptide Analog as Antiviral Agent. US patent WO20151914372015."},{"issue":"18","key":"10.1016\/j.ejmech.2026.119281_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241813778","article-title":"From benznidazole to new drugs: nanotechnology contribution in chagas disease","volume":"24","author":"Gomes","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119281_bib37","series-title":"Drugs and Lactation Database (Lactmed\u00ae)","author":"Benznidazole","year":"2006"},{"key":"10.1016\/j.ejmech.2026.119281_bib39","doi-asserted-by":"crossref","unstructured":"Morillo Carlos A, Marin-Neto Jose A, Avezum A, et al. Randomized trial of benznidazole for chronic chagas' Cardiomyopathy. N. Engl. J. Med.373(14):1295-1306.","DOI":"10.1056\/NEJMoa1507574"},{"key":"10.1016\/j.ejmech.2026.119281_bib40","unstructured":"Watson L, Inventor; Savant Neglected Diseases, LLC, Assignee. Making Benznidazole. US patent WO20172056222017."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119281_bib41","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.sxmr.2021.12.004","article-title":"Secnidazole for trichomoniasis in women and men","volume":"10","author":"Muzny","year":"2022","journal-title":"Sexual medicine reviews"},{"key":"10.1016\/j.ejmech.2026.119281_bib42","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2217\/fmb-2017-0270","article-title":"Secnidazole: next-generation antimicrobial agent for bacterial vaginosis treatment","volume":"13","author":"Nyirjesy","year":"2018","journal-title":"Future Microbiol."},{"key":"10.1016\/j.ejmech.2026.119281_bib43","author":"Multi-Center"},{"key":"10.1016\/j.ejmech.2026.119281_bib44","unstructured":"Jeanmart C, Messer M, Inventors; Rhone-Poulenc SA, Assignee. 1-(2-Hydroxypropyl)-2-methyl-5-nitro Imidazole. US patent DE21074231971."},{"issue":"14","key":"10.1016\/j.ejmech.2026.119281_bib45","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1007\/s40265-019-01187-w","article-title":"Bremelanotide: first approval","volume":"79","author":"Dhillon","year":"2019","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119281_bib46","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3390\/neurolint14010006","article-title":"Bremelanotide for treatment of female hypoactive sexual desire","volume":"14","author":"Edinoff","year":"2022","journal-title":"Neurol. Int."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119281_bib47","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1017\/S109285292100002X","article-title":"The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women","volume":"27","author":"Pfaus","year":"2022","journal-title":"CNS Spectr."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119281_bib48","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.bmcl.2004.12.025","article-title":"Detection and control of aspartimide formation in the synthesis of cyclic peptides","volume":"15","author":"Flora","year":"2005","journal-title":"Bioorganic & medicinal chemistry letters"},{"issue":"16","key":"10.1016\/j.ejmech.2026.119281_bib49","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1007\/s40265-019-01207-9","article-title":"Pretomanid: first approval","volume":"79","author":"Keam","year":"2019","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.ejmech.2026.119281_bib50","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ijtb.2020.09.003","article-title":"Pretomanid: the latest USFDA-Approved anti-tuberculosis drug","volume":"68","author":"Deb","year":"2021","journal-title":"Indian J. Tubercul."},{"key":"10.1016\/j.ejmech.2026.119281_bib52","unstructured":"Baker WR, Cai S, Keeler EL, Inventors; Pathogenesis Corporation, Assignee. Preparation of Bicyclic Nitroimidazole Antibacterial Compounds. US patent WO97015621997."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119281_bib53","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s40265-020-01277-0","article-title":"Osilodrostat: first approval","volume":"80","author":"Duggan","year":"2020","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.ejmech.2026.119281_bib54","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1159\/000522054","article-title":"Osilodrostat for cushing disease and its role in pediatrics","volume":"96","author":"Groselj","year":"2022","journal-title":"Horm. Res. Paediatr."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119281_bib55","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s11102-016-0742-1","article-title":"Updates on the role of adrenal steroidogenesis inhibitors in cushing's syndrome: a focus on novel therapies","volume":"19","author":"Fleseriu","year":"2016","journal-title":"Pituitary"},{"key":"10.1016\/j.ejmech.2026.119281_bib56","unstructured":"Ksander GM, Meredith E, Monovich LG, Papillon J, Firooznia F, Hu Q-Y, Inventors; Novartis A.-G. Novartis Pharma G.M.B.H., Assignee. Preparation of Condensed Imidazole Derivatives for the Inhibition of Aldosterone Synthase and Aromatase. US patent WO20070249452007."},{"issue":"10","key":"10.1016\/j.ejmech.2026.119281_bib57","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s40265-021-01544-8","article-title":"Remimazolam: a review in procedural sedation","volume":"81","author":"Lee","year":"2021","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.ejmech.2026.119281_bib58","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40265-020-01299-8","article-title":"Remimazolam: first approval","volume":"80","author":"Keam","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.119281_bib59","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.2147\/DDDT.S384155","article-title":"Remimazolam: an updated review of a new sedative and anaesthetic","volume":"16","author":"Hu","year":"2022","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejmech.2026.119281_bib60","volume":"vols. 12\u20132021","author":"Kilpatrick","year":"2021"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119281_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.17085\/apm.21115","article-title":"Remimazolam: pharmacological characteristics and clinical applications in anesthesiology","volume":"17","author":"Kim","year":"2022","journal-title":"Anesthesia and pain medicine"},{"key":"10.1016\/j.ejmech.2026.119281_bib62","unstructured":"Feldman PL, Jung DK, Kaldor I, Pacofsky GJ, Stafford JA, Tidwell JH, Inventors; Glaxo Group Limited, Assignee. Preparation of short-acting Benzodiazepines. US patent WO20000698362000."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119281_bib63","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s40265-021-01470-9","article-title":"Setmelanotide: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.ejmech.2026.119281_bib64","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S2213-8587(22)00277-7","article-title":"Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and alstr\u00f6m syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period","volume":"10","author":"Haqq","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.ejmech.2026.119281_bib65","unstructured":"Dong ZX, Inventor; Ipsen Pharma S.A.S, Assignee. Process for the Synthesis of Melanocortin Analog Ac-Arg-cyclo(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2. US patent WO20110603552011."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119281_bib66","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40265-019-1051-6","article-title":"First global approval","volume":"79","author":"Deeks","year":"2019","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.ejmech.2026.119281_bib67","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000923","article-title":"Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness","volume":"4","author":"Torreele","year":"2010","journal-title":"PLoS Neglected Trop. Dis."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119281_bib68","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3390\/tropicalmed5010029","article-title":"New drugs for human African trypanosomiasis: a twenty first century success story","volume":"5","author":"Dickie","year":"2020","journal-title":"Tropical medicine and infectious disease"},{"key":"10.1016\/j.ejmech.2026.119281_bib69","unstructured":"Parkanyi Z, Alattyani E, Bugir Z, Harsanyi M, Inventors; Drugs for Neglected Diseases Initiative (DNDI), Assignee. Process for Preparation of phenyloxymethyl-nitro-imidazole Derivatives Including Fexinidazole and Medicinal Use of Same. US patent WO20140794972014."},{"key":"10.1016\/j.ejmech.2026.119281_bib70","unstructured":"Winkelmann E, Raether W, Inventors; Hoechst A.-G., Assignee. 1-Methyl-2-(phenyloxymethyl)-5-nitroimidazoles. US patent DE25313031977."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119281_bib71","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40265-024-02002-x","article-title":"Nirogacestat: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119281_bib72","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41698-022-00308-1","article-title":"Molecular pathogenesis of desmoid tumor and the role of \u03b3-secretase inhibition","volume":"6","author":"Federman","year":"2022","journal-title":"npj Precis. Oncol."},{"issue":"9","key":"10.1016\/j.ejmech.2026.119281_bib73","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1016\/j.bmcl.2010.12.118","article-title":"Design, synthesis, and in vivo characterization of a novel series of tetralin amino imidazoles as \u03b3-secretase inhibitors: discovery of PF-3084014","volume":"21","author":"Brodney","year":"2011","journal-title":"Bioorganic & medicinal chemistry letters"},{"issue":"8","key":"10.1016\/j.ejmech.2026.119281_bib74","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1080\/10428194.2019.1602263","article-title":"FLT3 inhibitor quizartinib (AC220)","volume":"60","author":"Naqvi","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.ejmech.2026.119281_bib75","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1476-4598-12-19","article-title":"Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms","volume":"12","author":"Kampa-Schittenhelm","year":"2013","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119281_bib76","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-024-01617-7","article-title":"Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD-positive AML","volume":"17","author":"Cortes","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"23","key":"10.1016\/j.ejmech.2026.119281_bib77","doi-asserted-by":"crossref","first-page":"7808","DOI":"10.1021\/jm9007533","article-title":"Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor","volume":"52","author":"Chao","year":"2009","journal-title":"J. Med. Chem."},{"issue":"16","key":"10.1016\/j.ejmech.2026.119281_bib78","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1007\/s40265-017-0817-y","article-title":"Glecaprevir\/pibrentasvir: first global approval","volume":"77","author":"Lamb","year":"2017","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.ejmech.2026.119281_bib79","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02558-16","article-title":"In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS5A inhibitor pibrentasvir","volume":"61","author":"Ng","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.119281_bib80","series-title":"Principles and Practice of Pediatric Infectious Diseases","first-page":"1583","article-title":"295 - antiviral agents","author":"Kimberlin","year":"2023"},{"issue":"6","key":"10.1016\/j.ejmech.2026.119281_bib81","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.jinf.2019.10.007","article-title":"Consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection: public health England HCV resistance group","volume":"79","author":"Bradshaw","year":"2019","journal-title":"J. Infect."},{"issue":"9","key":"10.1016\/j.ejmech.2026.119281_bib82","doi-asserted-by":"crossref","first-page":"4052","DOI":"10.1021\/acs.jmedchem.8b00082","article-title":"Highlights of the structure-activity relationships of benzimidazole linked pyrrolidines leading to the discovery of the hepatitis C virus NS5A inhibitor pibrentasvir (ABT-530)","volume":"61","author":"Wagner","year":"2018","journal-title":"J. Med. Chem."},{"issue":"18","key":"10.1016\/j.ejmech.2026.119281_bib83","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1007\/s40265-017-0840-z","article-title":"Abemaciclib: first global approval","volume":"77","author":"Kim","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.119281_bib84","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13045-015-0194-5","article-title":"Palbociclib: a first-in-class CDK4\/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer","volume":"8","author":"Lu","year":"2015","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119281_bib85","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0092-8674(91)90181-W","article-title":"The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle","volume":"67","author":"Goodrich","year":"1991","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.ejmech.2026.119281_bib86","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1111\/cas.14419","article-title":"Abemaciclib induces atypical cell death in cancer cells characterized by formation of cytoplasmic vacuoles derived from lysosomes","volume":"111","author":"Hino","year":"2020","journal-title":"Cancer Sci."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119281_bib87","first-page":"949","article-title":"A synthesis of abemaciclib utilizing a leuckart\u2013wallach reaction","volume":"56","author":"Frederick","year":"2015"},{"issue":"20","key":"10.1016\/j.ejmech.2026.119281_bib88","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.2217\/fon-2017-0170","article-title":"A review of binimetinib for the treatment of mutant cutaneous melanoma","volume":"13","author":"Koelblinger","year":"2017","journal-title":"Future oncology (London, England)"},{"issue":"6","key":"10.1016\/j.ejmech.2026.119281_bib89","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1053\/j.seminoncol.2015.09.023","article-title":"MEK1\/2 inhibitors: molecular activity and resistance mechanisms","volume":"42","author":"Wu","year":"2015","journal-title":"Semin. Oncol."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119281_bib90","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1470-2045(13)70024-X","article-title":"MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study","volume":"14","author":"Ascierto","year":"2013","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119281_bib91","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11033-016-3943-9","article-title":"Extracellular signal-regulated kinase 1 and 2 in cancer therapy: a focus on hepatocellular carcinoma","volume":"43","author":"Mehdizadeh","year":"2016","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.ejmech.2026.119281_bib92","unstructured":"Wallace EM, Lyssikatos JP, Hurley BT, Marlow AL, Inventors; Array Biopharma, Inc, Assignee. Preparation of Phenylaminobenzimidazolecarboxylates as Mitogen Activated Protein Kinase Kinase (MEK) Inhibitors. US patent WO20030779142003."},{"key":"10.1016\/j.ejmech.2026.119281_bib93","unstructured":"Huang X, Peters M, Schumacher KM, et al., Inventors; Novartis Pharma AG Amgen Inc., Assignee. Combination Therapy. US patent WO20131421822013."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119281_bib94","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40265-018-1047-7","article-title":"Glasdegib: first global approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"issue":"20","key":"10.1016\/j.ejmech.2026.119281_bib95","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1158\/1078-0432.CCR-19-0365","article-title":"FDA approval summary: Glasdegib for newly diagnosed acute myeloid leukemia","volume":"25","author":"Norsworthy","year":"2019","journal-title":"Clin. Cancer Res. : an official journal of the American Association for Cancer Research"},{"issue":"10","key":"10.1016\/j.ejmech.2026.119281_bib96","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1158\/1078-0432.CCR-17-2824","article-title":"Phase Ib study of glasdegib, a hedgehog pathway inhibitor, in combination with standard chemotherapy in patients with AML or high-risk MDS","volume":"24","author":"Savona","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119281_bib97","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1021\/ml2002423","article-title":"Discovery of PF-04449913, a potent and orally bioavailable inhibitor of smoothened","volume":"3","author":"Munchhof","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"issue":"10","key":"10.1016\/j.ejmech.2026.119281_bib98","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/blood-2011-10-383752","article-title":"Targeting hedgehog in hematologic malignancy","volume":"119","author":"Irvine","year":"2012","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ejmech.2026.119281_bib99","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1111\/cas.13285","article-title":"Phase I study of glasdegib (PF-04449913), an oral smoothened inhibitor, in Japanese patients with select hematologic malignancies","volume":"108","author":"Minami","year":"2017","journal-title":"Cancer Sci."},{"issue":"10","key":"10.1016\/j.ejmech.2026.119281_bib101","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1038\/s41375-023-02001-z","article-title":"Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial","volume":"37","author":"Sekeres","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2026.119281_bib102","unstructured":"Munchhof MJ, Reiter LA, La Greca SD, Jones CS, Li Q, Inventors; Pfizer Inc., Assignee. Preparation of Benzimidazole Derivatives for Treatment of Abnormal Cell Growth. US patent US200900054162009."},{"issue":"12","key":"10.1016\/j.ejmech.2026.119281_bib103","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/trstmh\/trz093","article-title":"Triclabendazole in the treatment of human fascioliasis: a review","volume":"113","author":"Gandhi","year":"2019","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119281_bib104","first-page":"774","article-title":"Seroprevalence of human fascioliasis in chaharmahal and bakhtiyari province, Southwestern Iran","volume":"45","author":"Manouchehri Naeini","year":"2016","journal-title":"Iranian journal of public health"},{"issue":"10","key":"10.1016\/j.ejmech.2026.119281_bib105","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1111\/cts.13564","article-title":"Effects of triclabendazole and its metabolite exposure on the heart-rate-corrected QT intervals: a randomized, placebo- and positive-controlled thorough QT study in healthy individuals","volume":"16","author":"Prince","year":"2023","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.ejmech.2026.119281_bib106","unstructured":"Xu Y, Fan Z, Chen L, Dun W, Inventors; Wuhan Jiuzhou Yumin Pharmaceutical Technology Co., Ltd., Assignee. Preparation Method of Triclabendazole as Medicine for Treating Fascioliasis. US patent CN1110725702020."},{"key":"10.1016\/j.ejmech.2026.119281_bib107","unstructured":"Rane RA, Verma S, Arulmoli T, Inventors; Sequent Scientific Limited, Assignee. A Process for the Preparation of Triclabendazole. US patent WO20120700682012."},{"key":"10.1016\/j.ejmech.2026.119281_bib108","unstructured":"Jacquot R, Mercier C, Inventors; Rhone-Poulenc Chimie SA, Assignee. Tungsten Carbide as Catalyst for the Hydrogenation of Nitro or Nitroso Aromatic Compounds to Aromatic Amines. US patent EP5360701993."},{"issue":"9","key":"10.1016\/j.ejmech.2026.119281_bib109","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s40265-020-01331-x","article-title":"Selumetinib: first approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119281_bib110","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1186\/s12885-016-2773-4","article-title":"Selumetinib suppresses cell proliferation, migration and trigger apoptosis, G1 arrest in triple-negative breast cancer cells","volume":"16","author":"Zhou","year":"2016","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1016\/j.ejmech.2026.119281_bib111","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.bbamcr.2006.10.001","article-title":"Roles of the Raf\/MEK\/ERK pathway in cell growth, malignant transformation and drug resistance","volume":"1773","author":"McCubrey","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"issue":"4","key":"10.1016\/j.ejmech.2026.119281_bib112","doi-asserted-by":"crossref","first-page":"701","DOI":"10.4103\/idoj.idoj_569_23","article-title":"Selumetinib\u2014A comprehensive review of the new FDA-approved drug for neurofibromatosis","volume":"15","author":"Gorai","year":"2024","journal-title":"Indian Dermatology Online Journal"},{"issue":"15","key":"10.1016\/j.ejmech.2026.119281_bib113","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in children with inoperable plexiform neurofibromas","volume":"382","author":"Gross","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119281_bib114","doi-asserted-by":"crossref","unstructured":"Dombi E, Baldwin A, Marcus Leigh J, et al. Activity of selumetinib in neurofibromatosis type 1\u2013Related plexiform neurofibromas. N. Engl. J. Med.375(26):2550-2560.","DOI":"10.1056\/NEJMoa1605943"},{"key":"10.1016\/j.ejmech.2026.119281_bib115","unstructured":"Squire CJ, Demattei J, Roberts RJ, et al., Inventors; Array Biopharma Inc. Astrazeneca AB, Assignee. Crystal Forms of a 1H-benzimidazole-6-carboxamide Hydrogen Sulfate Salt. US patent WO20070762452007."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119281_bib116","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40265-022-01677-4","article-title":"Maribavir: first approval","volume":"82","author":"Kang","year":"2022","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.ejmech.2026.119281_bib117","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s11899-020-00557-6","article-title":"Moving past ganciclovir and foscarnet: advances in CMV therapy","volume":"15","author":"Hakki","year":"2020","journal-title":"Current hematologic malignancy reports"},{"issue":"8","key":"10.1016\/j.ejmech.2026.119281_bib118","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1128\/AAC.46.8.2373-2380.2002","article-title":"Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication","volume":"46","author":"Koszalka","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.119281_bib119","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2147\/TCRM.S303052","article-title":"Evaluating the safety of maribavir for the treatment of cytomegalovirus","volume":"18","author":"Gandhi","year":"2022","journal-title":"Therapeut. Clin. Risk Manag."},{"key":"10.1016\/j.ejmech.2026.119281_bib120","unstructured":"Chamberlain SD, Koszalka GW, Inventors; Wellcome Foundation Limited, Assignee. Preparation of benzimidazole-containing Nucleoside Analogs as Virucides. US patent WO96018331996."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119281_bib121","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s40265-022-01699-y","article-title":"Daridorexant: first approval","volume":"82","author":"Markham","year":"2022","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.ejmech.2026.119281_bib122","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1007\/s00213-021-05954-0","article-title":"Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia","volume":"238","author":"Roch","year":"2021","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.ejmech.2026.119281_bib123","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.12782","article-title":"Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications","volume":"28","author":"Herring","year":"2019","journal-title":"J. Sleep Res."},{"key":"10.1016\/j.ejmech.2026.119281_bib125","unstructured":"Boss C, Brisbare-Roch C, Brotschi C, et al., Inventors; Actelion Pharmaceuticals Ltd., Assignee. Preparation of benzimidazole-proline Derivatives for the Treatment of Sundown Syndrome. US patent WO20150830942015."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119281_bib126","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40265-024-02136-y","article-title":"Inavolisib: first approval","volume":"85","author":"Blair","year":"2025","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119281_bib127","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s12672-024-01252-1","article-title":"Momelotinib in myelofibrosis and beyond: a comprehensive review of therapeutic insights in hematologic malignancies","volume":"15","author":"Dadkhah","year":"2024","journal-title":"Discov. Oncol."},{"issue":"24","key":"10.1016\/j.ejmech.2026.119281_bib128","doi-asserted-by":"crossref","first-page":"16589","DOI":"10.1021\/acs.jmedchem.2c01422","article-title":"Discovery of GDC-0077 (inavolisib), a highly selective inhibitor and degrader of mutant PI3K\u03b1","volume":"65","author":"Hanan","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119281_bib129","first-page":"1","article-title":"Preclinical assessment of the PI3K\u03b1 selective inhibitor inavolisib and prediction of its pharmacokinetics and efficacious dose in human","author":"Salphati","year":"2024","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ejmech.2026.119281_bib130","unstructured":"Angelaud R, Bruetsch T, Gosselin F, Han C, Stutz A, Inventors; Genentech, Inc., Assignee. Process for the Preparation of Benzoxazepin Oxazolidinone Compounds. US patent WO20222515672022."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119281_bib131","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/13543784.2024.2305131","article-title":"Taletrectinib for the treatment of ROS-1 positive non-small cell lung cancer: a drug evaluation of phase I and II data","volume":"33","author":"Nagasaka","year":"2024","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"16","key":"10.1016\/j.ejmech.2026.119281_bib132","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1200\/JCO-25-00275","article-title":"Taletrectinib in ROS1+ non\u2013small cell lung cancer: trust","volume":"43","author":"P\u00e9rol","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119281_bib133","unstructured":"Zhou F, Chen DD, Guo F, Ren Z, Shang L, Wang H, Inventors; AnHeart Therapeutics (Hangzhou) Co., Ltd., Assignee. Method for Producing 3,6-disubstituted-imidazo[1,2-b]pyridazine Compounds. US patent WO20232209672023."},{"key":"10.1016\/j.ejmech.2026.119281_bib134","unstructured":"Takeda Y, Yoshikawa K, Kagoshima Y, et al., Inventors; Daiichi Sankyo Company,Limited, Assignee. Preparation of imidazo[1,2-b]pyridazine Derivatives as Potent Inhibitors of ROS1 Kinase and NTRK Kinase. US patent WO20131835782013."},{"key":"10.1016\/j.ejmech.2026.119281_bib135","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104896","article-title":"The development of zongertinib for HER2-mutant NSCLC","volume":"215","author":"Brazel","year":"2025","journal-title":"Crit. Rev. Oncol.-Hematol."},{"key":"10.1016\/j.ejmech.2026.119281_bib136","unstructured":"Boys ML, Ellis BD, Gaudino JJ, et al., Inventors; Array Biopharma Inc., Assignee. Pyrimido[5,4-d]pyrimidine Derivatives as HER2 Mutation Inhibitors. US patent WO20220035752022."},{"key":"10.1016\/j.ejmech.2026.119281_bib137","unstructured":"Wilding B, Boese D, Engelhardt H, et al., Inventors; Boehringer Ingelheim International Gmbh, Assignee. Synthesis of diazino-pyrimidines as Anticancer Agents. US patent WO20212138002021."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426007269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426007269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:05:55Z","timestamp":1793977555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426007269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":133,"alternative-id":["S0223523426007269"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119281","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FDA-approved imidazole- and benzimidazole-based drugs: An update","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119281","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119281"}}